Targeted inhibition of ubiquitin signaling reverses metabolic reprogramming and suppresses glioblastoma growth (vol 5, 780, 2022)COMMUNICATIONS BIOLOGYIF5.12024-10-290OAAI
Clinical Evaluation and Comparison of Two Microfluidic Antigenic Assays for Detection of SARS-CoV-2 VirusMICROORGANISMSIF4.22023-11-052OAAI
Targeted inhibition of ubiquitin signaling reverses metabolic reprogramming and suppresses glioblastoma growthCOMMUNICATIONS BIOLOGYIF5.12022-08-0210OAAI
Ageritin-The Ribotoxin-like Protein from Poplar Mushroom (Cyclocybe aegerita) Sensitizes Primary Glioblastoma Cells to Conventional Temozolomide ChemotherapyMOLECULESIF4.62022-04-072OAAI
Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma CellsTOXINSIF42021-09-2514OAAI
Gymnema sylvestre Extract Restores the Autophagic Pathway in Human Glioblastoma Cells U87MgBIOLOGY-BASELIF3.52021-09-040OAAI
Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumoursJOURNAL OF NEURO-ONCOLOGYIF3.12021-01-0412PREAI
Implication of Lactucopicrin in Autophagy, Cell Cycle Arrest and Oxidative Stress to Inhibit U87Mg Glioblastoma Cell GrowthMOLECULESIF4.62020-12-1015OAAI
Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington's diseaseHUMAN MOLECULAR GENETICSIF3.22019-10-2037PREAI
Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington's Disease Pre-clinical ModelFRONTIERS IN MOLECULAR NEUROSCIENCEIF3.82019-04-2431OAAI
CURCUMIN-SUPPLEMENTED DIET PRESERVES BODY WEIGHT AND AMELIORATES INTESTINAL FUNCTIONALITY IN R6/2 MICEJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-010PREAI
METABOLISM OF SIALO-CONJUGATES IS DEFECTIVE IN PRE-CLINICAL MODELS OF HUNTINGTON'S DISEASEJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-010OAAI
STIMULATION OF SPHK1 WITH SELECTIVE ACTIVATOR K6PC-5 IS BENEFICIAL IN THE TRANSGENIC R6/2 MOUSE MODEL OF HUNTINGTON DISEASEJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-010PRE
INHIBITION OF S1P DEGRADATION IS BENEFICIAL IN THE TRANSGENIC R6/2 MOUSE MODEL OF HUNTINGTON DISEASEJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-010PREAI
Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease (vol 7, 5280, 2017)SCIENTIFIC REPORTSIF3.92018-05-243OAAI
Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's diseaseHUMAN MOLECULAR GENETICSIF3.22018-04-2440OAAI
De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's DiseaseFRONTIERS IN NEUROSCIENCEIF3.22017-12-1947OAAI
Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's diseaseSCIENTIFIC REPORTSIF3.92017-07-1375OAAI
Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) miceSCIENTIFIC REPORTSIF3.92017-02-173OAAI
Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington DiseaseSCIENTIFIC REPORTSIF3.92017-01-2478OAAI